Supplemental Financial Information - Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net income (loss)	$ (496.7)	$ 1,284.7	$ 3,045.2
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	180.6	147.4	52.0
Equity-based compensation	249.1	154.0	163.1
Right-of-use asset impairment, net of broker fees	0.0	0.0	24.8
Non-cash performance allocations and incentive fees, net	1,572.8	393.6	(1,670.7)
Non-cash principal investment income	(123.9)	(553.4)	(618.5)
Other non-cash amounts	23.8	(10.3)	29.1
Purchases of investments	(301.2)	(629.9)	(276.7)
Proceeds from the sale of investments	472.2	474.9	668.4
Payments of contingent consideration	(68.6)	(5.7)	(48.0)
Changes in deferred taxes, net	(368.7)	(73.2)	508.4
Change in due from affiliates and other receivables	(33.4)	(82.5)	(25.7)
Change in deposits and other	6.3	(11.8)	(12.5)
Change in accounts payable, accrued expenses and other liabilities	(33.2)	(14.3)	105.7
Change in accrued compensation and benefits	10.6	(135.4)	239.0
Change in due to affiliates	(14.5)	1.7	0.2
Change in lease right-of-use asset and lease liability	(10.8)	(8.8)	4.5
Change in deferred revenue	15.3	4.5	35.1
Net cash provided by (used in) operating activities	204.9	(379.3)	1,791.0
Cash flows from investing activities
Purchases of corporate treasury investments	(187.3)	(69.6)	0.0
Proceeds from corporate treasury investments	210.3	50.0	0.0
Purchases of fixed assets, net	(66.6)	(40.6)	(41.4)
Purchase of Abingworth, net of cash acquired	0.0	(150.2)	0.0
Purchase of CBAM intangibles and investments	0.0	(618.4)	0.0
Net cash used in investing activities	(43.6)	(828.8)	(32.2)
Cash flows from financing activities
Borrowings under credit facilities	0.0	0.0	70.0
Repayments under credit facilities	0.0	0.0	(70.0)
Issuance of 4.625% subordinated notes due 2061, net of financing costs	0.0	0.0	484.1
Repurchase of 3.875% senior notes due 2023	0.0	0.0	(259.9)
Proceeds from CLO borrowings, net of financing costs	12.0	73.2	111.7
Payments on CLO borrowings	(17.2)	(16.7)	(232.5)
Payments of contingent consideration	0.0	0.0	(0.1)
Dividends to common stockholders	(497.7)	(443.6)	(355.8)
Payment of deferred consideration for Carlyle Holdings units	(68.8)	(68.8)	(68.8)
Contributions from non-controlling interest holders	177.0	391.2	216.2
Distributions to non-controlling interest holders	(139.7)	(216.8)	(94.6)
Common shares issued for performance allocations	0.0	38.9	4.8
Common shares repurchased	(203.5)	(185.6)	(161.8)
Change in due to/from affiliates financing activities	(62.3)	(81.2)	(68.7)
Net cash (used in) provided by financing activities	(99.6)	114.8	(242.5)
Effect of foreign exchange rate changes	18.9	(20.3)	(30.8)
Increase (decrease) in cash, cash equivalents and restricted cash	80.6	(1,113.6)	1,485.5
Cash, cash equivalents and restricted cash, beginning of period	1,361.5	2,475.1	989.6
Cash, cash equivalents and restricted cash, end of period	1,442.1	1,361.5	2,475.1
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	1,440.3	1,360.7	2,469.5
Restricted cash	1.8	0.8	5.6
Total cash, cash equivalents and restricted cash, end of period	1,442.1	1,361.5	2,475.1
Cash and cash equivalents held at Consolidated Funds	346.0	209.0	147.8
MRE
Cash flows from investing activities
Proceeds from sale, net of cash sold	0.0	0.0	5.9
Brazil management entity
Cash flows from investing activities
Proceeds from sale, net of cash sold	$ 0.0	0.0	3.3
Subordinated Notes Due 2061
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	4.625%
Subordinated Notes Due 2023
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	3.875%
Consolidated Operating Entities
Cash flows from operating activities
Net income (loss)	$ (579.3)	1,248.6	3,042.5
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	180.6	147.4	52.0
Equity-based compensation	249.1	154.0	163.1
Right-of-use asset impairment, net of broker fees	0.0	0.0	24.8
Non-cash performance allocations and incentive fees, net	1,569.2	387.5	(1,670.7)
Non-cash principal investment income	(130.7)	(501.5)	(628.9)
Other non-cash amounts	23.8	(10.3)	29.1
Purchases of investments	(345.8)	(737.7)	(384.5)
Proceeds from the sale of investments	485.9	498.0	708.3
Payments of contingent consideration	(68.6)	(5.7)	(48.0)
Changes in deferred taxes, net	(368.7)	(73.2)	508.4
Change in due from affiliates and other receivables	(33.5)	(82.3)	(25.1)
Change in deposits and other	6.3	(11.8)	(12.5)
Change in accounts payable, accrued expenses and other liabilities	(33.2)	(14.3)	105.7
Change in accrued compensation and benefits	10.6	(135.4)	239.0
Change in due to affiliates	(14.5)	1.7	0.2
Change in lease right-of-use asset and lease liability	(10.8)	(8.8)	4.5
Change in deferred revenue	15.3	4.5	35.1
Net cash provided by (used in) operating activities	955.7	860.7	2,143.0
Cash flows from investing activities
Purchases of corporate treasury investments	(187.3)	(69.6)	0.0
Proceeds from corporate treasury investments	210.3	50.0	0.0
Purchases of fixed assets, net	(66.6)	(40.6)	(41.4)
Purchase of Abingworth, net of cash acquired	0.0	(150.2)	0.0
Purchase of CBAM intangibles and investments	0.0	(618.4)	0.0
Net cash used in investing activities	(43.6)	(828.8)	(32.2)
Cash flows from financing activities
Borrowings under credit facilities	0.0	0.0	70.0
Repayments under credit facilities	0.0	0.0	(70.0)
Issuance of 4.625% subordinated notes due 2061, net of financing costs	0.0	0.0	484.1
Repurchase of 3.875% senior notes due 2023	0.0	0.0	(259.9)
Proceeds from CLO borrowings, net of financing costs	12.0	73.2	111.7
Payments on CLO borrowings	(17.2)	(16.7)	(232.5)
Payments of contingent consideration	0.0	0.0	(0.1)
Dividends to common stockholders	(497.7)	(443.6)	(355.8)
Payment of deferred consideration for Carlyle Holdings units	(68.8)	(68.8)	(68.8)
Contributions from non-controlling interest holders	11.8	9.2	19.4
Distributions to non-controlling interest holders	(64.0)	(78.7)	(74.5)
Common shares issued for performance allocations	0.0	38.9	4.8
Common shares repurchased	(203.5)	(185.6)	(161.8)
Change in due to/from affiliates financing activities	(16.2)	(456.2)	(68.7)
Net cash (used in) provided by financing activities	(843.6)	(1,128.3)	(602.1)
Effect of foreign exchange rate changes	12.1	(17.2)	(23.2)
Increase (decrease) in cash, cash equivalents and restricted cash	80.6	(1,113.6)	1,485.5
Cash, cash equivalents and restricted cash, beginning of period	1,361.5	2,475.1	989.6
Cash, cash equivalents and restricted cash, end of period	1,442.1	1,361.5	2,475.1
Supplemental cash disclosures
Issuance of common shares related to the acquisition of CBAM and Abingworth	0.0	219.5	0.0
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	1,440.3	1,360.7	2,469.5
Restricted cash	1.8	0.8	5.6
Total cash, cash equivalents and restricted cash, end of period	1,442.1	1,361.5	2,475.1
Cash and cash equivalents held at Consolidated Funds	346.0	209.0	147.8
Consolidated Operating Entities | MRE
Cash flows from investing activities
Proceeds from sale, net of cash sold	0.0	0.0	5.9
Consolidated Operating Entities | Brazil management entity
Cash flows from investing activities
Proceeds from sale, net of cash sold	$ 0.0	$ 0.0	$ 3.3
Consolidated Operating Entities | Subordinated Notes Due 2061
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	4.625%
Consolidated Operating Entities | Subordinated Notes Due 2023
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	3.875%